A novel CDK4 inhibitor for myeloid protection in chemotherapy-treated triple-negative breast Cancer.

ABSTRACT:

Background

Despite advances in cancer treatment, chemotherapy remains a cornerstone of clinical practice. However, its efficacy is often compromised by dose-limiting haematologic toxicities. Recent strategies aim to enhance chemotherapy tolerability while preserving its effectiveness. One emerging approach involves selective CDK4 inhibitors to serve as myeloid-protective agents in retinoblastoma (RB)-negative tumours, such as triple-negative breast cancer (TNBC). Because bone marrow (BM) cells rely on RB for proliferation, CDK4 inhibitors may protect these cells while sparing RB-deficient tumour cells. The present study investigated the potential of AU2-94, a first-in-class CDK4 inhibitor, to protect BM cells during myelosuppressive chemotherapy in TNBC, beyond its established appl

SUBMITTER: Safaroghli-Azar A 

PROVIDER: S-EPMC12310753 | biostudies-literature | 2025 Jun

REPOSITORIES: biostudies-literature